Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott C Bell

Showing results (161-170 of 203) with videos related to

Pageof 21
Sort By:
Age and Ageing|December 29, 2022
Targeted reduction of airborne viral transmission risk in long-term residential aged careAmanda Brass, Andrew P Shoubridge, Nicolas Larby, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|May 27, 2014
European Cystic Fibrosis Society Standards of Care: Best Practice guidelinesAlan R Smyth, Scott C Bell, Snezana Bojcin, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|February 8, 2016
A phase 3, multi-center, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of levofloxacin inhalation solution (APT-1026) in stable cystic fibrosis patientsPatrick A Flume, Donald R VanDevanter, Elizabeth E Morgan, et al.
Scientific Reports|November 18, 2022
Survival of people with cystic fibrosis in AustraliaRasa Ruseckaite, Farhad Salimi, Arul Earnest, et al.
Thorax|April 19, 2014
Viability of Pseudomonas aeruginosa in cough aerosols generated by persons with cystic fibrosisLuke D Knibbs, Graham R Johnson, Timothy J Kidd, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|January 17, 2015
A phase 3, open-label, randomized trial to evaluate the safety and efficacy of levofloxacin inhalation solution (APT-1026) versus tobramycin inhalation solution in stable cystic fibrosis patientsJ Stuart Elborn, David E Geller, Douglas Conrad, et al.
Respirology (Carlton, Vic.)|March 2, 2023
Thoracic Society of Australia and New Zealand (TSANZ) position statement on chronic suppurative lung disease and bronchiectasis in children, adolescents and adults in Australia and New ZealandAnne B Chang, Scott C Bell, Catherine A Byrnes, et al.
Mbio|July 18, 2013
Within-host evolution of Burkholderia pseudomallei over a twelve-year chronic carriage infectionErin P Price, Derek S Sarovich, Mark Mayo, et al.
Clinical Microbiology Reviews|August 19, 2024
Practical Guidance for Clinical Microbiology Laboratories: Updated guidance for processing respiratory tract samples from people with cystic fibrosisLisa Saiman, Valerie Waters, John J LiPuma, et al.
International Journal of Environmental Research and Public Health|October 27, 2022
The Effectiveness of Ultraviolet-C (UV-C) Irradiation on the Viability of Airborne <i>Pseudomonas aeruginosa</i>Thi Tham Nguyen, Congrong He, Robyn Carter, et al.
Pageof 21

Showing results (161-170 of 203) with videos related to

Sort By:
Pageof 21
Age and Ageing|December 29, 2022
Targeted reduction of airborne viral transmission risk in long-term residential aged careAmanda Brass, Andrew P Shoubridge, Nicolas Larby, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|May 27, 2014
European Cystic Fibrosis Society Standards of Care: Best Practice guidelinesAlan R Smyth, Scott C Bell, Snezana Bojcin, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|February 8, 2016
A phase 3, multi-center, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of levofloxacin inhalation solution (APT-1026) in stable cystic fibrosis patientsPatrick A Flume, Donald R VanDevanter, Elizabeth E Morgan, et al.
Scientific Reports|November 18, 2022
Survival of people with cystic fibrosis in AustraliaRasa Ruseckaite, Farhad Salimi, Arul Earnest, et al.
Thorax|April 19, 2014
Viability of Pseudomonas aeruginosa in cough aerosols generated by persons with cystic fibrosisLuke D Knibbs, Graham R Johnson, Timothy J Kidd, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|January 17, 2015
A phase 3, open-label, randomized trial to evaluate the safety and efficacy of levofloxacin inhalation solution (APT-1026) versus tobramycin inhalation solution in stable cystic fibrosis patientsJ Stuart Elborn, David E Geller, Douglas Conrad, et al.
Respirology (Carlton, Vic.)|March 2, 2023
Thoracic Society of Australia and New Zealand (TSANZ) position statement on chronic suppurative lung disease and bronchiectasis in children, adolescents and adults in Australia and New ZealandAnne B Chang, Scott C Bell, Catherine A Byrnes, et al.
Mbio|July 18, 2013
Within-host evolution of Burkholderia pseudomallei over a twelve-year chronic carriage infectionErin P Price, Derek S Sarovich, Mark Mayo, et al.
Clinical Microbiology Reviews|August 19, 2024
Practical Guidance for Clinical Microbiology Laboratories: Updated guidance for processing respiratory tract samples from people with cystic fibrosisLisa Saiman, Valerie Waters, John J LiPuma, et al.
International Journal of Environmental Research and Public Health|October 27, 2022
The Effectiveness of Ultraviolet-C (UV-C) Irradiation on the Viability of Airborne <i>Pseudomonas aeruginosa</i>Thi Tham Nguyen, Congrong He, Robyn Carter, et al.
Pageof 21